Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
- PMID: 32931713
- PMCID: PMC7737599
- DOI: 10.1164/rccm.202006-2511LE
Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
Comment in
-
Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.Am J Respir Crit Care Med. 2020 Dec 15;202(12):1733-1734. doi: 10.1164/rccm.202007-2913LE. Am J Respir Crit Care Med. 2020. PMID: 32931711 Free PMC article. No abstract available.
Comment on
-
Thromboprophylaxis in COVID-19: Anti-FXa-the Missing Factor?Am J Respir Crit Care Med. 2020 Aug 1;202(3):455-457. doi: 10.1164/rccm.202005-1654LE. Am J Respir Crit Care Med. 2020. PMID: 32510975 Free PMC article. No abstract available.
References
-
- COVID-19 Treatment Guidelines Panel. Bethesda, MD: National Institutes of Health; 2020. Coronavirus disease 2019 (COVID-19) treatment guidelines. [accessed 2020 Feb 8]. Available from: https://www.covid19treatmentguidelines.nih.gov/ - PubMed
-
- Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1859–1865. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical